Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Company Information
About this company
Key people
Frank D. Heuszel
Chairman of the Board, Chief Executive Officer
Todd D. Macko
Chief Financial Officer
Mark Suseck
Chief Operating Officer
Heng Fai Chan
Director
Jason Grady
Director
Elise Brownell
Independent Director
Castel B. Hibbert
Independent Director
David K. Keene
Independent Director
Click to see more
Key facts
- Shares in issue104.62m
- EPICIBO
- ISINUS45259L2051
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$52.52m
- Employees2
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.